Medical journalists need improved conflict-of-interest standards, say Dartmouth researchers

Nov 19, 2008

Two Dartmouth researchers call for greater scrutiny of the relationship between medical journalists and the health care industries they cover. Their study was published online today, Nov. 19, in the British Medical Journal, or BMJ.

The BMJ paper outlines three areas where journalists might become entangled in conflict-of-interest issues: during educational activities that may be drug company sponsored, when accepting sponsored awards, or in the day-to-day practice of reporting the news by relying too heavily on industry supplied sources.

"The media play a role as society's watchdogs," says Steven Woloshin, an author on the paper and an associate professor of medicine and of community and family medicine at Dartmouth Medical School (DMS). "Good medical journalism can expose links between doctors and rewards from pharmaceutical companies. But who's looking to see whether the journalists are being influenced?"

Co-authors on the paper, titled "Who's Watching the Watchdogs? Medical Journalism and Entanglement," are Lisa Schwartz, associate professor of medicine and of community and family medicine at DMS, and Ray Moynihan with the School of Medicine and Public Health at the University of Newcastle in Australia. Schwartz and Woloshin are also affiliated with the Veteran's Affairs Outcomes Group and the Center for Medicine and the Media at The Dartmouth Institute for Health Policy and Clinical Practice.

The authors believe relationships between drug companies and journalists might result in more favorable news stories, in a similar fashion to how industry funding of medical research is associated with more favorable research outcomes.

Regarding education, Woloshin says, "Corporate funding and sponsorships are not new to academia, but we think that there is the possibility that a sponsor could subtly invoke a sense of loyalty from a journalist. There should be no such temptation for journalism students or their teachers."

The authors were surprised by the widespread business of pharmaceutical and other healthcare businesses offering cash prizes and travel benefits to journalists. The paper states, "… we believe journalists accepting these prizes are clearly creating conflicts-of-interest for themselves" and calls for journalists to stop accepting these sponsored awards.

Schwartz says that the practice of medical journalism has evolved to blur the lines between traditional news reporting and producing advertising materials that mimic reporting. News corporations, which depend on advertising, need to be especially vigilant in maintaining a separation between their editorial mission and their advertising sales.

"Journalists also need to clearly disclose when their sources have ties to industry, whether they are quoting patient groups, opinion leaders, or patients referred to them by an industry public relations office," says Schwartz. "The problem with compelling anecdotes of treatment success is that they may represent the exception, rather than a more typical experience. This can mislead audiences."

To enhance credibility and reestablish trust in the media, the authors recommend similar steps to those being taken in the medical field: journalists and organizations that train journalists should not accept funding or prizes from healthcare industries, and journalists should routinely divulge their own conflicts of interest and those of their sources.

"The news media plays a vital role," says Woloshin. "If medical journalists compromise, or appear to compromise, their independence, society loses."

Source: Dartmouth College

Explore further: Amgen misses 1Q views as higher costs cut profit

add to favorites email to friend print save as pdf

Related Stories

Cutting through the rhetoric on hunters vs. wildlife

Jan 22, 2014

The recent Timemagazine cover story "America's Pest Problem (Time to Cull the Herd)" pairs a provocative headline with a photograph of a slender white-tailed doe in a dewy wood. Although not a regular re ...

Scientific evidence: What is it and how can we trust it?

Jul 04, 2013

The phrase "scientific evidence" has become part of the vernacular – thrown about like a hot potato during discussions of major environmental, health or social issues. Climate change is one example. The ...

Former Sony CEO Stringer to retire

Mar 11, 2013

Howard Stringer, the first foreigner to lead Japanese electronics giant Sony during some of its most challenging times, has announced he will retire from the struggling firm.

Science denied: Why does doubt persist?

Oct 12, 2012

The sign in front of the tall display case at the Smithsonian Institution's Museum of Natural History lures visitors to "meet one of your oldest relatives." Inside stands a morganucodon, a mouse-like animal ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories